<DOC>
	<DOCNO>NCT00901836</DOCNO>
	<brief_summary>The goal study evaluate radiation treatment intend increase chance cure sarcoma decrease side effect proton therapy . This study also look tumor tissue remove initial biopsy final surgery information may help treat retroperitoneal sarcoma future .</brief_summary>
	<brief_title>Preoperative Proton Radiotherapy Retroperitoneal Sarcoma</brief_title>
	<detailed_description>Data collection obtain patient 's medical record include initial evaluation , pathology report , dosimetry information , radiotherapy completion record follow-up .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Patients must histologicallyconfirmed intermediate high grade retroperitoneal sarcoma histologic subtype . Primary recurrent disease isolate single intraabdominal retroperitoneal region allow . Tumor must consider potentially completely resectable define cross sectional imaging ( 360o encasement superior mesenteric artery , aorta , inferior vena cava , iliac artery iliac vein extension tumor vertebral column ) . At least 2 week must elapse prior surgery hormonal therapy . Patients must ≤ grade 1 acute toxicity prior treatment anticancer modality ( return baseline status note recent treatment ) . Patients persist , stable chronic toxicity prior treatment ≤ grade 1 eligible . Age ≥18 year time consent . Life expectancy great 3 month . Physician document . Women childproducing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation subsequent 6 month . Patients must negative serum pregnancy test within 2 week prior begin treatment trial . Sexually active men must also use appropriate contraception method father child receive therapy study . Ability understand willingness sign write Institutional Review Board ( IRB ) stamp study specific inform consent document undergo research relate procedure study treatment . Biopsy require pathologic confirmation intermediate high grade sarcoma pathology review University Florida . Agree allow tissue use current study . Receiving investigational agent . Evidence metastatic disease . Uncontrolled intercurrent illness and/or psychiatric illness/social situation would limit compliance study requirement . Pregnant nursing woman exclude study radiotherapy may potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother agent , breastfeed discontinue mother treat . All herbal and/or alternative medication discontinue study , include , limited : Hydrastis canadensis ( goldenseal ) , Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia . Requirement treatment immunosuppressive agent chronic steroid . Previous intraabdominal retroperitoneal radiotherapy . Treatment cytotoxic agent and/or treatment biologic agent within 4 week prior begin treatment study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sarcoma</keyword>
</DOC>